How effective is the Lao Lucius version of Adagraxibu?

Laos Lucius version of Adagrasib (Adagrasib) is a targeted therapy drug specifically targeting KRAS G12C mutant non-small cell lung cancer (NSCLC) and others with KRAS G12Cmalignant tumors. Adagrasib prevents the proliferation and spread of tumor cells by selectively inhibiting the activity of KRAS G12C mutants. The Laos Lucius version of adagrasib is similar to the original drug in terms of efficacy and safety, providing some patients with a more user-friendly treatment option.

The efficacy of the Laos Lucius version of adagrasib in KRAS G12C mutation-positive patients is consistent with that of the original drug. Multiple clinical studies have shown that adagrasib can effectively inhibit the tumor growth of KRAS G12C mutated lung cancer and produce significant curative effects in some patients. In clinical trials, adagrasib's objective response rate (ORR) performed well, with patients' tumors significantly shrinking and their disease stabilization time prolonged. For those patients who have failed other treatments, adagrasib has shown good therapeutic effects as a new treatment option.

Similar to the original drug, the side effects of the Laos Lucius version of adagrasibu are relatively mild, mainly including fatigue, nausea, loss of appetite, diarrhea, etc. Most side effects are mild to moderate and may be relieved with supportive care. A small number of patients may experience more serious side effects, such as abnormal liver function or difficulty breathing. Therefore, the patient's liver function and other related indicators need to be regularly monitored during treatment. Overall, the Laos Lucius version of adagrasibu is well tolerated, and most patients can successfully complete treatment.

The drug composition of the Laos Lucius version of adagrasibu is consistent with the original drug, which means that it has the same therapeutic mechanism and effect at the molecular level. Although it is a generic drug, the Laos Lucius version of adagrasibu is as effective as the original drug in the treatment of KRAS G12C mutated non-small cell lung cancer, providing patients with a more economical option with the same therapeutic effect. For some patients with limited financial conditions, generic drugs are undoubtedly a more people-friendly choice, which can reduce the patient's financial burden while ensuring the treatment effect.

References：https://www.krazati.com/